These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 3133943

  • 21. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L, Keuppens F, Mahler C, Debruyne FM, Weil EH, Lunglmayr G, Newling D, Robinson MR, Richards B, Smith PH.
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH, Hirdes WH, Schröder FH, de Jong FH, Kwekkeboom DJ, van't Veen AJ, Sandow J, Krauss B.
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI, Falkson G, Falkson HC.
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [Abstract] [Full Text] [Related]

  • 25. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
    Kerle D, Williams G, Ware H, Doble A, Allen J, Bloom SR.
    Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Results of long term treatment of advanced prostatic cancer with the LHRH analogue buserelin.
    Fontana D, Randone DF, Isaia GC, Colombo M, Giusti M, Bellina M, Rolle L, Fasolis G.
    Prog Clin Biol Res; 1987 Mar 01; 243A():239-41. PubMed ID: 3116548
    [No Abstract] [Full Text] [Related]

  • 32. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
    Falkson G, Vorobiof DA.
    J Clin Oncol; 1987 Sep 01; 5(9):1419-23. PubMed ID: 3114438
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM, Karthaus HF, Schröder FH, de Voogt HJ, de Jong FH, Klijn JG.
    Prog Clin Biol Res; 1985 Sep 01; 185A():251-70. PubMed ID: 3929265
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.